News

The funding has been awarded for four product programs, including the company’s differentiated anti-IL17 monoclonal antibody (mAb) program. AnaptysBio said that the QTDP grant awards will help fund

Assisted by its accounting firm Langdon & Co of Garner, the grant application submitted by Yukon resulted in this grant in furtherance of its ‘development of a safe,

Lilly said that Effient analysis involved 346 patients with acute coronary syndrome (ACS) who had received either study drug and subsequently underwent isolated CABG at some point during

The Phase II TOMORROW study was a 12-month, randomised, double-blind, placebo-controlled trial, aimed to evaluate the impact of oral BIBF1120 on decline in forced vital capacity (FVC) in

Loss from operations was $908,465, compared to $1.29m for the comparable period in 2009. For the nine months ended 30 September 2010 Catalyst posted a net loss of

According to China Biologic Products, the revenue growth was primarily attributable to price increases ranging from 6.2% to 55.8% across the company’s approved product categories, with the exception

Invented and developed by Neogenix, the antibody has shown anti-tumor effects for both pancreatic and colorectal tumors in both in-vitro and animal studies and may have both therapeutic

Pixantrone is a new aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Previously, the Pediatric Committee (the